In clinic, the low tumour-targeted ability of SOD is a critical shortage in its application, which is a difficulty for scientist at all time. For solving this problem, Nostoc commune CHEN iron-superoxide dismutase (Fe-SOD) and anti-lung adenocarcinoma LC-1 single chain Fv (ScFv) were fused, and the fusion protein named SOD-ScFv was expressed. After purification, fusion protein demonstrated both SOD and LC-1 antibody activities. The result of tracing of SOD-ScFv by FITC dyeing and quantification of ROS(reactive oxygan species) in SPC-A-1(lung adenocarcinoma) cells showed that the fusion protein possessed the ability to recognize SPC-A-1 cells and eliminate the cellular ROS. The tumour-targeted theory put up in this research will overcome two applied disadvantages of SOD in clinic: it neither target the tumour cell nor permeates through the cell membrane. Also, the research provides a feasible idea that ScFv can be used to target the anticancer drug to tumour.